Skip to main content

Table 1 Baseline characteristics of the patients recruited

From: Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

Characteristic

 

Overall (n = 8)

Age (years, Median (Q1,Q3))

 

24.5 (20.2,34.5)

Gender

Male

7 (87.5%)

Female

1 (12.5%)

Performance Status

0

6 (75.0%)

1

2 (25.0%)

Histology/Cytological type

Chondroblastic OS 9181/3

1 (12.5%)

Osteoblastic OS 9180/3

2 (25.0%)

Osteosarcoma NOS 9180/3

5 (62.5%)

Primary Site

axial

3 (37.5%)

limb

5 (62.5%)

Disease stage at screening

metastatic

8 (100.0%)

Tumour size at baseline (sum of longest diameters) (mm)

82.0 (51.0,92.0)

Prior radiotherapy

yes

2 (25.0%)

no

6 (75.0%)

Prior chemotherapy

yes

8 (100.0%)

no

0 (0.0%)

Prior surgery

yes

8 (100.0%)

no

0 (0.0%)